64992-03-6

Basic information

• Product Name: 4-(bromomethyl)-2-fluoropyridine
• Synonyms: 4-(bromomethyl)-2-fluoropyridine
• CAS NO: 64992-03-6
• Molecular Formula: C₆H₅BrFN
• Molecular Weight: 190.0130032
• Mol File: 64992-03-6.mol
• Article Data: 20

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(bromomethyl)-2-fluoropyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(bromomethyl)-2-fluoropyridine(64992-03-6)
• EPA Substance Registry System: 4-(bromomethyl)-2-fluoropyridine(64992-03-6)

Safety Data

• Hazardous Substances Data: 64992-03-6(Hazardous Substances Data)

Usage

Uses

4-Bromomethyl-2-fluoropyridine, is a building block used in the synthesis of various chemical compounds.

Upstream product

• 461-87-0 2-fluoro-4-methylpyridine 
• 128-08-5 N-Bromosuccinimide 

Downstream Products

• 1029689-75-5 (2-methoxypyridin-4-yl)methanamine hydrochloride 
• 368426-85-1 5-(azidomethyl)-2-fluorobenzonitrile 
• 777056-79-8 1-(2-fluoropyridin-4-yl)methanamine 
• 1006302-17-5 3-[[3-(2-fluoro-pyridin-4-ylmethyl)-5-isopropyl-2,6-dioxo-1,2,3,6-tetrahydro-pyrimidin-4-yl]-(4-methoxy-benzyloxyimino)-methyl]-5-methyl-benzonitrile 
• 1006300-11-3 Benzoic acid 2-fluoro-pyridin-4-ylmethyl ester 

Relevant articles and documents

In vitro and in vivo evaluation of fluorinated indanone derivatives as potential positron emission tomography agents for the imaging of monoamine oxidase B in the brain

Monoamine oxidases (MAOs) play a key role in the metabolism of major monoamine neurotransmitters. In particular, the upregulation of MAO-B in Parkinson's disease, Alzheimer's disease and cancer augmented the development of selective MAO-B inhibitors for d

MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the preparation, pharmaceutical composition and the use of compound formula (I).

Synthesis, in Vitro Evaluation, and Radiolabeling of Fluorinated Puromycin Analogues: Potential Candidates for PET Imaging of Protein Synthesis

There is currently no ideal radiotracer for imaging of protein synthesis rate (PSR) by positron emission tomography (PET). Existing fluorine-18-labeled amino acid-based radiotracers predominantly visualize amino acid transporter processes, and in many cases they are not incorporated into nascent proteins at all. Others are radiolabeled with the short-half-life positron emitter carbon-11, which is rather impractical for many PET centers. Based on the puromycin (6) structural manifold, a series of 10 novel derivatives of 6 was prepared via Williamson ether synthesis from a common intermediate. A bioluminescence assay was employed to study their inhibitory action on protein synthesis, which identified the fluoroethyl analogue 7b as a lead compound. The fluorine-18 analogue was prepared via nucleophilic substitution of the corresponding tosylate precursor in a modest radiochemical yield of 2 ± 0.6% with excellent radiochemical purity (>99%) and showed complete stability over 3 h at ambient temperature.